Obesity

Orlistat is a non-systemic inhibitor of gastrointestinal lipases.

Orlistat is minimally absorbed from the gastrointestinal tract. The major route of elimination is via the feces (primarily unabsorbed drug); less than 5% of a dose appears in the urine. A small degree of biliary excretion may occur.

Hypersensitivity to orlistat, chronic mal-absorption syndrome, cholestasis, organic causes of obesity

X

No data available

Adverse effects of orlistat have been limited to the gastrointestinal tract, and include soft or liquid stools, oily/fatty stools, increased defecation, fecal incontinence, abdominal pain, oily spotting, nausea, and vomiting. Orlistat can reduce serum levels of fat-soluble vitamins, particularly vitamin E, and vitamin supplementation may be indicated in selected patients.

Adults: obesity: 120 mg PO TID with fat-containing meals, during or up to 1 hr after the meal. Omit dose if meal is occasionally missed or contains no fat.